News

Austedo Adherence Rates Higher Than Xenazine’s, US Study Finds

People with Huntington’s disease are more likely to take Austedo (deutetrabenazine) as directed, compared with the similar medication Xenazine (tetrabenazine), according to a new study. The study also found lower discontinuation rates with Austedo, which may suggest that, between these two treatments for chorea, Austedo tends to…

Top 10 Huntington’s Disease Stories of 2021

Throughout 2021, Huntington’s Disease News brought you daily coverage of the latest scientific findings, treatment developments, and clinical trials related to Huntington’s disease. As a reminder of what mattered most to you last year, here are the top 10 most-read articles of 2021 with a brief description of what made…

Branaplam on FDA’s Fast Track; Phase 2 Trial Now Enrolling

The experimental oral medication branaplam (LMI070) has been granted fast track designation by the U.S. Food and Drug Administration (FDA) as a potential treatment for Huntington’s disease, according to an announcement from the therapy’s developer, Novartis. This designation is designed to speed the development and review of…

Valbenazine Eases Chorea in Trial; FDA Submission Expected Next Year

Treatment with valbenazine significantly lessened chorea — a motor symptom characterized by jerky, unpredictable, and involuntary movements — in people with Huntington’s disease in the Phase 3 clinical trial KINECT-HD, according to an announcement from the therapy’s developer, Neurocrine Biosciences. Neurocrine now is planning to submit an…

KINECT-HD2 Study of Oral Valbenazine for Chorea Enrolling

The Huntington Study Group is seeking 30 patients to join KINECT-HD2, an open-label study of oral valbenazine capsules for chorea, or jerky involuntary movements, in Huntington’s disease, a press release states. KINECT-HD2 is an extension study of KINECT-HD (NCT04102579), a Phase 3 clinical trial that tested…

FDA Places Prilenia’s Oral Pridopidine on Fast Track

The U.S. Food and Drug Administration (FDA) has given fast track designation to Prilenia Therapeutics’ pridopidine as a potential oral treatment for Huntington’s disease. This designation is given to therapies that show considerable potential in addressing serious conditions for which available treatments fall short. It is meant to…

HDSA’s 7th Annual Freeze HD Event Raises $211K to Help Families

Celebrities turned out in force — albeit virtually — to support the 7th Annual Freeze HD event, hosted by the Huntington’s Disease Society of America (HDSA), which raised more than $211,000 to help improve the lives of families affected by Huntington’s disease (HD). The 2.5-hour show, held online for…

Hereditary Disease Foundation Awards Prizes to Leaders in Research

Two scientists investigating Huntington’s disease have been awarded prizes by the Hereditary Disease Foundation, recognizing their leadership in disease research. The Leslie Gehry Brenner Prize for Innovation in Science was awarded to Elena Cattaneo, PhD, director of the Laboratory of Stem Cell Biology and Pharmacology of Neurodegenerative Diseases…